Emergent BioSolutions Inc. (EBS)
After hours:
| Previous Close | 2.2900 |
| Open | 2.2700 |
| Bid | 0.0000 x 3200 |
| Ask | 0.0000 x 2200 |
| Day's Range | 2.1400 - 2.2985 |
| 52 Week Range | 1.4200 - 10.8800 |
| Volume | |
| Avg. Volume | 3,041,235 |
| Market Cap | 114.212M |
| Beta (5Y Monthly) | 1.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -14.8500 |
| Earnings Date | May 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
GlobeNewswireEmergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
GAITHERSBURG, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business updates, revenue guidance for the second quarter of 2024, and financial outlook for full year 2024. Conference Call InformationParticipants can access the conference call live via webcast. To participate via telephone, please register in advance at this
Simply Wall St.Institutional owners may take dramatic actions as Emergent BioSolutions Inc.'s (NYSE:EBS) recent 16% drop adds to one-year losses
Key Insights Significantly high institutional ownership implies Emergent BioSolutions' stock price is sensitive to...
GlobeNewswireAquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
Appoints Abigail “Abbey” Jenkins, a veteran biotech executive with over 20 years of experience in commercial leadership, to Board of DirectorsWARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Abigail Jenkins to the Company’s Board of Direct
